Key result
CRT upgrade from RVP linked to ~370% higher 1-year mortality versus de novo CRT.
Why the study?
While CRT improves outcomes in HF patients with LBBB, the benefits of CRT in patients with previous pacing remain uncertain.
Does upgrading to CRT from right ventricular pacing affect short-term mortality compared to de novo CRT implantation in heart failure patients with LVEF <35%?
Cohort (n=93)
Does upgrading to CRT from right ventricular pacing affect short-term mortality compared to de novo CRT implantation in heart failure patients with LVEF <35%?
Effect estimate: HR 4.7 (95% CI 2.2-9.9)
p-value: p=<0.001
Upgrading to CRT from right ventricular pacing is associated with significantly higher short-term mortality compared to de novo CRT implantation in heart failure patients.
Background: Cardiac resynchronization therapy (CRT) improves outcomes in heart failure (HF) patients with left bundle branch block (LBBB).However, the benefits of CRT in patients with previous pacing are still uncertain.The aim is to compare the short-term mortality between upgrade and De novo-CRT implantation.Methods: Prospective cohort study that included HF patients indicated for CRT with left ventricular ejection fraction (LVEF) of less than 35%.Data were collected to investigate mortality predictors after 1 year.The overall survival was calculated by the Kaplan-Meier method and multivariate analysis using Cox's regression model was performed.A value of p<0.05 was considered as significant.Results: 93 patients were evaluated with a mean follow-up of 1.0±0.6year.Of these, 22 (23.7%) were upgraded from right ventricular pacing.Chagas Disease (CD) was the most prevalent cause of HF with 29 (31.2%)individuals.LVEF at 6 months increased after CRT: 24,0%±7.8 to 30.3%±11.5, p=0.007, and there was no difference between upgraded patients and De novo CRT, p=0.26.Overall mortality at 1-year was 30.1% (28 patients).In univariate analysis, CD and upgraded therapy were associated with high mortality, HR: 3.9, CI 1.8-8.4,p=0.001 and HR: 4.7, CI: 2.2-9.9,p<0.001, respectively.
No takes yet. Share an insight, caveat, or question.
Viana et al. (2023) conducted a cohort in Heart failure (n=93). Upgrade to CRT from right ventricular pacing vs. De novo-CRT implantation was evaluated on Overall mortality at 1-year (HR 4.7, 95% CI 2.2-9.9, p=<0.001). Upgrading to cardiac resynchronization therapy from right ventricular pacing was associated with significantly higher 1-year mortality compared to de novo CRT (HR 4.7; 95% CI 2.2-9.9; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: